TrialReader


Atorvastatin as an Adjunct to DFDBA in Intrabony Defects

NCT03009097 — Phase 4, Completed, 26 participants, Kamineni Institute of Dental Sciences

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

"Comparative Evaluation Of The Efficacy Of Atorvastatin Gel As An Adjunct To Allografts In The Treatment Of Intrabony Defects" - A Clinico Radiological Study

RegistryNCT03009097
StatusCompleted
PhasePhase 4
Study typeInterventional; randomized, parallel, masking: single, treatment
Enrollment26 (Actual)
SponsorKamineni Institute of Dental Sciences (Other)
ConditionsChronic Periaortitis, Intrabony Periodontal Defect
InterventionsDFDBA, DFDBA with atorvastatin (Biological, drug)
Datesstart 2013-04-01, primary completion 2014-08-01, completion 2014-08-01, first posted 2017-01-04, last updated 2017-01-04

Related Papers Related Patents Related Grants Related Experts
AI Assistant Save
All trials for Chronic Periaortitis All trials for Intrabony Periodontal Defect All trials of DFDBA All trials of DFDBA with atorvastatin

-Summary

Periodontitis is a major oral health problem which leads to the progressive destruction of periodontal ligament and alveolar bone with pocket formation, recession or both. The ultimate goal of periodontal therapy is to regenerate the lost periodontal tissue. The most common form of regenerative periodontal therapy is the use of bone grafts which stimulate bone formation by the processes of osteoinduction and osteoconduction.

Statins are a group of lipid lowering drugs which inhibit bone resorption by inhibition of the enzyme HMG-CoA reductase. They also stimulate new bone formation by local stimulation of BMP-2, a major bone growth regulatory factor. They also have anti-inflammatory and anti oxidant properties.

Very few studies exist evaluating the beneficiary effects of grafts if combined with the statins which might enhance the regeneration by bone grafts.

Hence, the present study was carried out in an attempt to comparatively evaluate clinically and radiologically, the efficacy of atorvastatin gel as an adjunct to allograft in the treatment of intrabony defects.

Expand all sections  ·  Collapse all

+Detailed description

A total of 26 intrabony defects in patients with chronic periodontitis as diagnosed by radiographs, were selected for the study after taking an informed consent. The selected sites were randomized in 2 treatment groups.

Group I - sites were treated with allograft (DFDBA) Group II - sites were treated with allograft (DFDBA) in combination with Atorvastatin gel.

Clinical parameters like probing depth and clinical attachment level and radiological assessment of intrabony defect fill were done at baseline and 3 and 6 months postoperatively.

+Arms and interventions

ArmTypeInterventionsDescription
DFDBAActive comparatorBiological: DFDBA13 intrabony defects in chronic periodontitis patients were treated with DFDBA
DFDBA with AtorvastatinActive comparatorDrug: DFDBA with atorvastatin13 intrabony defects in chronic periodontitis patients were treated with DFDBA in combination with Atorvastatin gel.
  • DFDBA (Biological), also known as Allograft: 13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA)
  • DFDBA with atorvastatin (Drug), also known as atorvastatin gel: 13 intrabony defects in chronic periodontitis patients were treated with allograft (DFDBA) in combination with atorvastatin gel

+Outcome measures

Primary outcomes

  • bone fill in mm was measured by taking radiographs [6 months]

+Eligibility

Sex: All, ages: 18 Years to 55 Years

Inclusion Criteria:

1. Systemically healthy individual based on personal and medical history.
2. Presentation of untreated Chronic Periodontitis with intrabony defect having probing pocket depth (PPD) ≥5mm or clinical attachment loss of ≥ 3mm and radiographic signs of angular bone loss.

Exclusion Criteria:

1. Patients diagnosed and treated for systemic disease
2. Pregnant and Lactating women
3. Smokers
4. History of allergy to statin group or patients on systemic statin therapy.
5. History of antibiotic or periodontal therapy for the past 6 months.

+Publications

  • Pradeep AR, Kumari M, Rao NS, Martande SS, Naik SB. Clinical efficacy of subgingivally delivered 1.2% atorvastatin in chronic periodontitis: a randomized controlled clinical trial. J Periodontol. 2013 Jul;84(7):871-9. doi: 10.1902/jop.2012.120393. Epub 2012 Oct 2. PMID 23030241

+Investigators

My Notes